Study Title
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Study Details
Description:
To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).
Sponsor:
MD Anderson Cancer Center
Contacts:
Eric Jonasch, MD (Principal Investigator)ejonasch@mdanderson.org
(713) 563-7232
Government Study Link:
NCT05663710 - Click here to see study onClinicalTrials.gov
